Bi/CNS 150 David Helfgott, Copenhagen Philharmonic, 1995 (as in movie “Shine”) Wednesday December 3, 2013 Schizophrenia Bruce Cohen August Strindberg, self-portrait 1891 Kandel, Chapter 62 1 Case History of David Helfgott •Born in Melbourne 1947 •1962-1970 several schizoaffective episodes •1966-70 Royal College of Music •1970-1980 Hospitalized in Australia •1984- present concert pianist •1996 biographical drama Shine based on life of Helfgott David Helfgott playing Rachmaninov Piano Concerto #3 (Copenhagen Philharmonic, 1995) According to the biography by his wife (2000), his medication was: (1) chlorpromazine, a D2 receptor blocker for schizophrenia (2) an anticholinergic for tardive dyskinesia. 2 What is schizophrenia? • “Schizophrenia is a thought disorder, characterized by illogical thinking, lack of reasoning, and inability to recognize reality” from Meyer and Quenzer, Psychopharmacology, 2012 • Disturbances in perception (hallucinations) common, particularly auditory hallucinations such as hearing commanding or insulting voices • Delusions (beliefs not based on reality) also common • Speech can be disturbed (ungrammatical, vague, confused, repetitive) • Inappropriate or absent emotional responses (blunted affect) 3 Clinical Signs of Schizophrenia Prodromal signs: “he was weird, even as a child” social isolation & withdrawal, impairment in roles of normal function; odd behavior & ideas; blunted affect; poor personal hygiene Positive signs: delusions, hallucinations, thought disorder (relieved by D2 antagonists) Negative signs: decreased motivation (avolition), diminished emotional expression, social withdrawal, anhedoinia Cognitive signs: impairments in attention, executive function, some types of memory (negative and cognitive symptoms resistant to antipsychotic drug treatment) Motor abnormalities: Posturing, impaired coordination, “catatonia” 4 Genetic risk of schizophrenia 100% identical twins 48% 17% fraternal twins children 50% siblings Concordance for Lifetime Risk of Schizophrenia parents shared DNA half siblings 25% grandchildren nephews/nieces uncles/aunts 12.5% 1st cousins general population 1% (~ independent of culture) 0% Several distinct genes (or sets of genotypes) can independently cause the disease 10% 20% Genetically Multifactorial Nongenetic or epigenetic factors are required, or the disease is inherently stochastic 30% Polygenic 40% 50% The disease occurs only if several genotypes are present together Partially Penetrant Similar to Kandel, Figure 62-1 5 2009 3.1 1.0 We describe a map of 1.42 million single nucleotide polymorphisms (SNPs) distributed throughout the human genome, providing an average density on available sequence of one SNP every 1.9 kilobases. This high-density SNP map provides a public resource for defining haplotype variation across the genome, and should help to identify biomedically important genes for diagnosis and therapy. International HapMap project A haplotype is a common pattern of several nearby SNPs: 2 SNPs, only 3 of 4 possible haplotypes exist 6 Hunting for Genes with SNPs Controls sequence A1 20% Schizophrenics 20% sequence A1 Locus A Chomosome 12 sequence A2 no linkage to schizophrenia sequence A2 80% 80% 40% 70% Locus B Chomosome 8 sequence B1 sequence B1 may be near a gene that helps to cause schizophrenia sequence B2 sequence B2 60% 30% 7 8p21, site of recent schizophrenia linkages, including these genes: neuregulin-1, frizzled-3, vesicular monoamine transporter-1, calcineurin Aγ, early growth response-1 1 mm Alberts 4-11 © Garland 8 Large deletions associated with schizophrenia PLoS Genetics, Feb 2009 •Very rare, large DNA deletions and duplications contribute to or explain a minority of schizophrenia cases . . . •One event deletes a gene known to interact with DISC1, a gene known to cause psychiatric problems in one family •DISC1 stands for “Disrupted in Schizophrenia 1” •DISC1 defect is linked to bipolar/schizophrenia phenotype in 80% of large Scottish family •DISC1 protein appears to regulate a variety of developmental and mitochondrial process CNVs are copy number variations 9 Anatomical correlates of schizophrenia Increased size of cerebral ventricles •Increased lateral and 3rd ventricle volume, and decreased grey matter is highly replicated finding •Ventricular enlargement is found in affected twinsof monozygotic pairs discordant for schizophrenia. •This enlargement appears to be stable when patients are followed up prospectively. Unaffected twin Figure 62-3 Schizophrenic twin Decreased cortical gray matter (not shown here, Figure 62-2, 62-6) Evident in superior temporal gyrus, dorsal prefrontal cortex and limbic areas such as the hippocampus and anterior cingulate cortex. These abnormalities can be found in never-medicated patients. 10 Histological correlates of schizophrenia • Schizophrenia associated with modest reductions in number of neurons in hippocampus and dorsolateral prefrontal cortex • In studies of monozygotic twins discordant for schizophrenia, there is diminished activation of the dorsolateral prefrontal cortex as measured by SPECT and PET. Subcellular neuronal abnormalities in schizophrenia Reduction in dendridic spines in prefrontal cortex- layer 3 compared to unaffected individuals Unaffected Schizophrenic #1 Schizophrenic #2 (Kandel, Figure 62-4) 11 Neuronal activity during hallucinations Neuro-imaging shows neuronal circuits involving the thalamus, caudateputamen, anterior cingulate, limbic cortex, auditory cortex, hippocampus and parahippocampal gyrus are activated in schizophrenics during auditory hallucinations. Part of Kandel, Figure 60-2 12 Nongenetic risk factors for schizophrenia • Nourishment and health of the fetus (study of Dutch children born during Nazi occupation) • Maternal viral infection during pregnancy (late Prof. Paul Patterson, Caltech) • Traumatic head injury 13 Endophenotypes (intermediate phenotypes) for schizophrenia 1. Sensory gating (habituation) deficit 2. Eye pursuit deficits 3. Deficits in working memory 14 Auditory gating measured electrophysiologically in hippocampus (CA3 layer) C57/BL6 WT 100 V 100 ms Voltage Mouse Audio (a) Observed in schizophrenics (~90%) but in only 8% of the general population (b) Autosomal dominant transmission, even in healthy relatives of schizophrenics (c) This trait maps to the vicinity of the α7 nicotinic receptor on chromosome 15. A, abnormal response ratio schizophrenic Human a N, normal response ratio Freedman et al, PNAS, 1996 15 Therapeutic approaches Effective clinical dose of “classical” or “typical” antipsychotic drugs correlates best with binding affinity for dopamine D2 receptor (See Figure 62-7) 16 Hospitalization of schizophrenics Population of US Public Mental Insitutions 600 thousands 500 400 300 200 100 0 1800 1850 1900 1950 2000 2050 year 1955, chlorpromazine 17 Three effects of Gi-coupled receptors Regulators of G protein Signaling tune the kinetics of effector (GIRK channel) activation/deactivation CHO CHO GIRKs Expressed: muscarinic ACh Receptor + GIRK . . . Decreased cAMP . . .+ RGS RGS4 a a Gene activation RGS GTP GTP GDP + Pi 25 receptor Gαi An effect of 5-HT in the hippocampus Activation of the 5-HT1A receptor on pyramidal cells hyperpolarizes the membrane, as does baclofen, an agonist of GABAB receptors. Effects of both the 5HT1A receptor and the GABAB receptor are blocked by pertussis toxin (PTX), which inactivates a class of Gproteins. outside from Lecture 12 G protein i q s t membrane a a inside effector channel enzyme intracellular messenger Ca2+ cAMP The pathway from GPCR to gene activation cytosol kinase phosphorylated protein nucleus How fast? 10 s to days How far? Up to 1 m 18 How do antipsychotic drugs work? “All current antipsychotic drugs exert their full therapeutic actions over weeks, suggesting that, like lithium and antidepressants, slowly developing adaptations (in this case to initial D2 dopamine receptor blockade) are required for their antipsychotic effects.” S. E. Hyman, E. Nestler, R. Malenka, 2008 Molecular Neuropharmacology : A Foundation for Clinical Neuroscience, 2nd Edition 19 The sensory gating anomaly maps near the α7 nicotinic acetylcholine receptor; 90% of schizophrenics smoke; α7 agonists and allosteric modulators are being tested for cognitive enhancement in schizophrenia. a10 a9 20 End of Schizophrenia Lecture Bi/CNS 150 Bruce Cohen’s office hours, Wednesday 1:15-2:00 328 Kerchhoff 21